Chronic inflammation in the promotion of lung carcinogenesis

doi:10.3760/cma.j.issn.1673-422X.2014.12.009

Abstract

Abstract: Chronic inflammation is proved to play an important role in promoting carcinogenesis. Many factors in inflammatory microenvironment, such as inflammatory immune cells, pro-inflammatory cytokines, inflammatory mediators, and aberrantly activated transcription factors of proinflammatory pathway (NF-κB, STAT3), have been found to provide a microenvironment for lung neoplastic processes, and promote the lung carcinogenesis. On the other hand, many antiinflammatory agents have been shown having inhibitory effects on lung tumorigenicity. With further understanding of the molecular links between inflammation and lung tumorigenesis, antiinflammation would provide alternative strategies for prevention and therapy of lung cancer.

Key words: Inflammation, Lung neoplasm, NF-kappa B

YANG Rui-Xu, DENG Jiong. Chronic inflammation in the promotion of lung carcinogenesis[J]. Journal of International Oncology, 2014, 41(12): 906-909.

References

［1］ Morrison WB. Inflammation and cancer: a comparative view［J］. J Vet Intern Med, 2012, 26(1): 1831. ［2］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. ［3］ Houghton AM. Mechanistic links between COPD and lung cancer［J］. Nat Rev Cancer, 2013, 13(4): 233245. ［4］ Lim WY, Chuah KL, Eng P, et al. Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and risk of lung cancer［J］. Lung Cancer, 2012, 77(2): 246251. ［5］ Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic nonsmall cell lung cancer (NSCLC): a retrospective review［J］. BMC Cancer, 2013, 13: 158. ［6］ Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer［J］. Adv Exp Med Biol, 2014, 816: 123. ［7］ Duan MC, Zhong XN, Liu GN, et al. The Treg/Th17 Paradigm in Lung Cancer［J］. J Immunol Res, 2014, 2014: 730380. ［8］ Lee JJ, Kim HJ, Yang CS, et al. A HighAffinity Protein Binder that Blocks the IL6/STAT3 Signaling Pathway Effectively Suppresses NonSmall Cell Lung Cancer［J］. Mol Ther, 2014, 22(7): 12541265. ［9］ Wang R, Lu M, Zhang J, et al. Increased IL10 mRNA expression in tumorassociated macrophage correlated with late stage of lung cancer［J］. J Exp Clin Cancer Res, 2011, 30: 62. ［10］ Jeon HS, Jen J. TGFbeta signaling and the role of inhibitory Smads in nonsmall cell lung cancer［J］. J Thorac Oncol, 2010, 5(4): 417419. ［11］ Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species［J］. J Toxicol Environ Health B Crit Rev, 2008, 11(1): 115. ［12］ Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL6 production in human lung adenocarcinomas［J］. J Clin Invest, 2007, 117(12): 38463856. ［13］ Tao Q, Fujimoto J, Men T, et al. Identification of the retinoic acidinducible Gprc5a as a new lung tumor suppressor gene［J］. J Natl Cancer Inst, 2007, 99(22): 16681682. ［14］ Deng J, Fujimoto J, Ye XF, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NFkappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis［J］. Cancer Prev Res (Phila), 2010, 3(4): 424437. ［15］ Chen Y, Deng J, Fujimoto J, et al. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor［J］. Cancer Res, 2010, 70(21): 89178926. ［16］ Zhan P, Qian Q, Yu LK. Prognostic value of COX2 expression in patients with nonsmall cell lung cancer: a systematic review and metaanalysis［J］. J Thorac Dis, 2013, 5(1): 4047. ［17］ Speranza L, De Lutiis MA, Shaik YB, et al. Localization and activity of iNOS in normal human lung tissue and lung cancer tissue［J］. Int J Biol Markers, 2007, 22(3): 226231. ［18］ Stathopoulos GT, Sherrill TP, Cheng DS, et al. Epithelial NFkappaB activation promotes urethaneinduced lung carcinogenesis［J］. Proc Natl Acad Sci U S A, 2007, 104(47): 1851418519. ［19］ Peters S, Meylan E. Targeting receptor activator of nuclear factorkappa B as a new therapy for bone metastasis in nonsmall cell lung cancer［J］. Curr Opin Oncol, 2013, 25(2): 137144. ［20］ Zhao X, Sun X, Li XL. Expression and clinical significance of STAT3, PSTAT3, and VEGFC in small cell lung cancer［J］. Asian Pac J Cancer Prev, 2012, 13(6): 28732877. ［21］ Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NFkappaB activity in tumors［J］. Cancer Cell, 2009, 15(4): 283293. ［22］ Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of nonsmall cell lung cancer by Gquartet oligonucleotides［J］. Int J Oncol, 2007, 31(1): 129136. ［23］ Yan C, Ding X, Wu L, et al. Stat3 downstream gene product chitinase 3like 1 is a potential biomarker of inflammationinduced lung cancer in multiple mouse lung tumor models and humans［J］. PLoS One, 2013, 8(4): e61984.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	He Guangsi, Wang Jun, Feng Mengmeng. Predictive value of inflammatory markers of peripheral blood cells on prognosis in the advanced non-small cell lung cancer with immune therapy [J]. Journal of International Oncology, 2023, 50(6): 321-327.
[4]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[5]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[6]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[7]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[8]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[9]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[10]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[11]	Liu Yonghong, Xue Lingbo, Bai Yang, Jin Jian, Zang Chunxia, Zhang Bo, Li Jie. Predictive value of systemic inflammation response index before treatment for pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy [J]. Journal of International Oncology, 2022, 49(4): 210-215.
[12]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[13]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[14]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[15]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.